Evommune (EVMN) grants director 15,673 stock options at $19.82

Rhea-AI Filing Summary

Evommune, Inc. director Benjamin F. McGraw III received a grant of stock options covering 15,673 shares of common stock. The options have an exercise price of $19.82 per share and expire on June 1, 2036.

According to the footnote, these options vest at the earlier of the first anniversary of the grant date or the company’s next annual meeting of stockholders, provided he remains in continuous service through that date. Following this grant, he holds options to acquire 15,673 shares directly. This is a routine compensation-related award, not an open-market share purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider MCGRAW BENJAMIN F III

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to buy)	15,673	$0.00	--

Holdings After Transaction: Stock Option (Right to buy) — 15,673 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 15,673 options Exercise price: $19.82 per share Expiration date: June 1, 2036 +2 more

5 metrics

Options granted 15,673 options Stock Option (Right to buy) awarded to director

Exercise price $19.82 per share Conversion or exercise price of options

Expiration date June 1, 2036 Option expiration date

Underlying shares 15,673 shares Common stock underlying the options

Post-transaction options 15,673 options Total options held following transaction

Key Terms

Stock Option (Right to buy), grant/award acquisition, conversion or exercise price, vesting, +1 more

5 terms

Stock Option (Right to buy) financial

"security_title: "Stock Option (Right to buy)""

grant/award acquisition financial

"transaction_action: "grant/award acquisition""

conversion or exercise price financial

"conversion_or_exercise_price: "19.8200""

vesting financial

"shares subject to the option award shall vest at the earlier"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholders financial

"the Issuer's next annual meeting of stockholders"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MCGRAW BENJAMIN F III

(Last) (First) (Middle)

C/O EVOMMUNE, INC.

1891 PAGE MILL ROAD

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Evommune, Inc. [ EVMN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to buy)	$19.82	06/02/2026		A		15,673		(1)	06/01/2036	Common Stock	15,673	$0.00	15,673	D

Explanation of Responses:

1. The shares subject to the option award shall vest at the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.

Remarks:

	/s/ Gregory S. Moss, Attorney-in-Fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Evommune (EVMN) report for Benjamin F. McGraw III?

Evommune reported that director Benjamin F. McGraw III received a grant of 15,673 stock options. These options give him the right to buy Evommune common shares at a fixed exercise price, functioning as equity-based compensation rather than an open-market stock purchase or sale.

How many Evommune (EVMN) shares are covered by the new stock options?

The new stock option award covers 15,673 shares of Evommune common stock. Each option entitles the holder to purchase one share at the specified exercise price once vesting conditions are satisfied, aligning the director’s potential upside with future company performance.

What is the exercise price and expiration date of the Evommune (EVMN) options?

The options have an exercise price of $19.82 per share and expire on June 1, 2036. This means the director can choose to buy shares at $19.82 any time after vesting and before that expiration date, subject to the award’s terms.

What is the vesting schedule for Benjamin F. McGraw III’s Evommune (EVMN) options?

The options vest at the earlier of the first anniversary of the grant date or the date of Evommune’s next annual stockholder meeting. Vesting also requires Benjamin F. McGraw III to remain in continuous service with the company through the applicable vesting date.

Did the Evommune (EVMN) Form 4 show any open-market stock purchases or sales?

No open-market purchases or sales were reported. The Form 4 discloses a grant of stock options classified as a compensation-related acquisition, not a market trade. The director’s transaction code is “A,” indicating a grant, award, or other acquisition of derivative securities.

How many Evommune (EVMN) options does Benjamin F. McGraw III hold after this grant?

After this grant, Benjamin F. McGraw III holds stock options to acquire 15,673 Evommune common shares directly. The filing’s totals reflect this entire amount as his position following the reported transaction, with no additional derivative holdings listed in the derivative summary.